Registration and Breakfast

Welcome – live-streamed and recorded 
Dr Flic Gabbay FRCP, FFPM (President, FPM)

Housekeeping and overview of themes
Dr Karen Mullen MBBS, FRCP, FFPM (event chair)

Life sciences innovation, impact on public health and the role of pharmaceutical medicine – live-streamed and recorded 

Pharmaceutical medicine is at the heart of research and development in the United Kingdom. According to Life Sciences Minister George Freeman earlier this year, the higher education sector in the UK accounted for some £2.2 billion of R&D in the medical and health sciences, or 0.10% of GDP. The UK’s business sector, meanwhile, in 2020 accounted for some £5 billion of pharmaceutical R&D, the latest in a several year upwards trend. In this session, our panellists discuss how this upward trajectory can be maintained in the future as the route from innovation to implementation becomes ever faster.       

Prof Kevin Fenton CBE, PrFPH, PhD, FRCP (President of the Faculty of Public Health and the Regional Director for London in the Office for Health Improvement and Disparities (OHID))
Sir Jonathan Symonds CBE (Chairman of the Board of GSK)
Moderator: Dr Flic Gabbay FRCP, FFPM (President of the Faculty of Pharmaceutical Medicine)

‘Public health considerations are essential to pharmaceutical medicine because they help to ensure that medicines are developed, used, and regulated in a way that protects and promotes the health of the population.

Public health experts inform the development of new medicines by identifying unmet needs and prioritising research into diseases and conditions that have a significant public health impact. They also play a role in the regulation of medicines and develop guidance on their appropriate use in clinical practice.

In the future, public health considerations are likely to become even more important in pharmaceutical medicine due to the increasing prevalence of chronic diseases, the growing threat of antimicrobial resistance, and the emergence of new infectious diseases.’ Prof Kevin Fenton (2023)

Zero to AI – live-streamed and recorded 

This session takes the audience from “Zero to AI” by cultivating a first principles understanding of software engineering, machine learning, deep learning, and ultimately, generative AI. The material is closely aligned with and inspired by the well-received “Applied AI in Healthcare” course that Dr Tirshan Panch teaches at the Harvard TH Chan School of Public Health. It is designed to set the scene for the other talks and interactive sessions to follow.

Dr Trishan Panch MD, MPH (President, Harvard TH Chan School of Public Health Alumni Association)

Meet our event partners

Your choice of:

Global Health: An end-to-end opportunity to drive health equity – live-streamed and recorded 

Join this breakout session to hear about novel approaches to accelerate medicines R&D and access in low resource settings. Speakers from different sectors will discuss the challenges and opportunities in developing and delivering health innovations to patients worldwide, with examples of open-innovation capacity-building, delivering clinical trials in neglected diseases and the use of technology to provide healthcare in remote areas. Gain insights into how you can promote health equity in your own role in pharmaceutical medicine.

Sameer Sawarkar (Co-Founder & CEO – Neurosynaptic Communications Pvt. Ltd.) [online]
Dr Craig Tipple MRCP, PhD (Medical Director at DnDI)
Dr Juliet Addo (Academic Engagement Director, Global Health & Head of the Africa Open Lab at GSK)
Chair: Dr Pauline Williams CBE, FMedSci, FFPM (Independent Consultant in Global Health and Translational Medicine)

Decoding genomics: promise and perils for pharmaceutical physicians

Join this breakout session to explore the exciting potential of genomics technology applications in clinical medicine, drug development and their potential for impact on pharmaceutical medical practice. Listen to our speakers from Genomics England and The Nuffield Council on Bioethics discuss how genomics can change the trajectory of medicine towards greater personalised and precision-based care. What are examples of the successes, the challenges and the ethical concerns we may be facing as we step into the future?

Prof Frances Flinter (Emeritus Professor of Clinical Genetics)
Parker Moss (Chief Ecosystems and Partnership Officer)
Chair: Dr Jeymi Tambiah MBChB, FRCS, MS, FAPCR, MFPM(Dis) (Senior Vice President, Clinical Development and External Innovation, Biosplice Therapeutics, San Diego)

How to leverage Artificial Intelligence in Pharmaceutical Medicine : Practical Examples in the Real World

Are you clear how you can make the most of the AI/ML revolution?

Our workshop will expose you to real-world scenarios where AI has been implemented, and what’s next.

1. Join us to learn how AI can transform the R&D process in the life sciences and beyond
2. Discover how AI can help solve health inequalities and improve access to care for underserved populations
3. Hear how AI can augment and enhance Medical Safety’s traditional approaches
4. Let us then all discuss the practicalities of AI implementation in the industry

Dr Trishan Panch MD, MPH (President, Harvard TH Chan School of Public Health Alumni Association)
Dr Rav Seeruthun FFPM (Chief Medical Officer and co-founder of health-equity.ai)
Chair: Dr Andrew Bate PhD (VP & Head, Safety Innovation & Analytics, GSK)

Lunch, partners exhibition, and networking

Climate, health and equity: a business critical and patient centric opportunity for industry leadership – live-streamed and recorded 

This session will explore business critical and patient centric opportunities emerging from the rapid transition to sustainable healthcare globally and in the UK.  After inspiring keynote presentations, an expert panel will be convened to discuss why climate and health is relevant for pharmaceutical physicians and the potential for improving patient outcomes through integrating climate and health actions.

Dr Emma Iovoli MFPM, MBChB, MRCP UK, MSc, PhD, Dip Pharm Med(Life Sciences Consultant – Climate and Health)
Dr Alan Dangour (Director of Climate and Health, Wellcome Trust)
Dr Ashton Harper (Head of Medical Affairs for Roche Diagnostics UK & Ireland)
Dr Fiona Adshead (Chair, Sustainable Healthcare Coalition)
Chair: Dr Pauline Williams CBE, FMedSci, FFPM (Independent Consultant in Global Health and Translational Medicine)

Your choice of:

Pharma’s Paradigm Shift: Harnessing the Power of Patient Innovators and Disrupters for Healthcare Transformation – live-streamed and recorded 

Hear first-hand from our panel of experienced patient advocates who have personally contributed to scientific innovation through collaboration with pharma and other stakeholders.  Gain valuable insights into the transformative impact of having a patient on your team.  Get their ideas on how you can work with them share their passion, wisdom and experience to enhance projects, products and initiatives and see how collaboration paves the way for more effective, ethical and patient-focused solutions.

Seb Tucknott (Founder and CEO of IBDrelief)
Clare Campbell-Cooper (Global Head of Digital Health and Innovation at Fortrea)
Dr Rich Gorman (Research Fellow at Brighton and Sussex Medical School)
Graeme Johnston (Founder member and current Board and Executive Committee member of Patient Focused Medicines Development (PFMD))
Chair: Dr Liz Clark MBBS, MSc, FFPM, FCMI, FInstLM (Visiting Lecturer and Patient Engagement Theme Lead at the Centre for Pharmaceutical Medicines Research)

Accelerated Access to Medicines – Regulatory and Reimbursement

Getting medicines to patients can be a bumpy road. Regulators offer multiple pathways for accelerating timelines and approvals to smooth that path, but it doesn’t stop there – reimbursement and HTA acceptance often prove to be further barriers.

The panel will discuss the early routes for access you may wish to consider, including some top tips for success. Then be ready with your questions as we also delve into the EU Regulation on Health Technology Assessment and what that its application in January 2025 means for you.

Rachel Cummings (Principal Consultant at Decisive Consulting)
Dr Julie Warner PhD (Vice President, Regulatory Affairs at Boyds)
Chair: Dr Kirsty Wydenbach MFPM (Head of Regulatory Strategy at Weatherden)

A different future: communicating about medicines safety within promotion

How many hours of your life have you spent reviewing and discussing efficacy messaging? And how many discussing safety messaging? Have you ever been to a brand team meeting where the only topic was what to communicate to health professionals about a medicine’s safety profile (when there wasn’t some sort of crisis). Isn’t it time we took safety communication seriously and dispensed with bland nonsense like ‘generally well tolerated’? Is it time we just thought about it more? Multiple recent ABPI Code cases would suggest it is.

Join us as we get three different perspectives on what good communication about medicines safety is.

Dr Amit Aggarwal MFPM (Executive Director for Medical Affairs at the ABPI)
Dr Alison Cave (Chief Safety Officer, Medicines and Healthcare products Regulatory Agency)
Chair: Dr Nick Broughton MFPM (Educator and Founding Partner, Ethos Pharmaceutical Ethics and Compliance Ltd.)

Meet our event partners

My Medical Department

Dr Marcia Philbin (FPM, Chief Executive)

How can the UK life sciences ecosystem work to encourage drug development and enable access? – live-streamed and recorded 

In 2021 the UK Government published its Life Sciences Vision to focus on what Government, the NHS, Regulators, Companies & Medical Charities must do to allow the pharmaceutical industry to grow and succeed in the UK, thereby bringing real benefits for patients through the NHS. During this panel session we will discuss what progress has been made and are the objectives of the vision being achieved.

Dr David Jefferys FFPM (Senior Vice President, Eisai)
Dr June Raine DBE FFPM (CEO of the Medicines and Healthcare products Regulatory Agency)
Prof Andrew Farmer (Professor of General Practice, University of Oxford and Director, NIHR Health Technology Assessment Programme)
Dr Lisa Broad PhD (Vice President and Head of Neurodegeneration Discovery, Lilly and Managing Director of Lilly Research Labs, UK)

Moderator: Prof Alan Boyd FRSB, FFLM, FRCP, FMedSci, FFPM (Past-President of FPM and CEO of Boyds)

Dr Flic Gabbay PFPM (President, FPM) –live-streamed and recorded 

Drinks reception and networking